To study the effectiveness and impact on the quality of life of patients with subclinical and clinically pronounced anxiety disorder of a mobile application in combination with Adaptol therapy

Close metadata

OBJECTIVE

To study the effectiveness and the quality of life impact of the mobile application Zdorovye.ru in people with subclinical and clinical anxiety disorder (AD).

MATERIAL AND METHODS

200 patients with more than 7 points on the Hospital Anxiety and Depression Scale (HADS) were included. Participants were randomized into two groups: experimental one (EG, n=133) — to receive standard treatment with temgicoluril (Adaptol), 500 mg (Olainfarm JSC, Latvia) and the Zdorovye.ru application; control group (CG, n=52) — standard treatment with temgicoluril (Adaptol).

RESULTS

There were a significant decrease in the HADS-A score, PSS-10 score and an increase in the visual analog scale EQ-5D score in both groups after 3 months of treatment (p<0.001). Clinical improvement was noticeable after 1.5 months in EG group: a decrease in HADS-A scores (p=0.001) and in tension and stress on PSS-10 subscales (p<0.001) were noted. This effect was not observed in the CG. After 3 months, all participants noted an improvement in quality of life (p<0.001), without a statistically significant difference between groups (p=0.233). The application left a positive impression on users and doctors — most respondents rated it as useful and clear.

CONCLUSION

Taking temgicoluril (Adaptol) for 3 months led to symptoms decrease and the quality of life and well-being improvement in patients with AD. Using the mobile application Zdorovye.ru in conjunction with drug therapy made it possible to achieve a clinical effect earlier, in 1.5 months.

Keywords:

anxiety disorder

mobile application

temgicoluril

Adaptol

quality of life

stress

Authors:

Levin O.S.

Russian Medical Academy for Continuing Professional Education

SPIN RSCI: 5342-1373
Scopus AuthorID: 57147160800
ORCID: 0000-0003-3872-5923

Received:

30.05.2024

Accepted:

04.06.2024

List of references:

Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dial Clin Neurosci. 2015;17(3):327-335. https://doi.org/10.31887/dcns.2015.17.3/bbandelow
World Health Organization. Mental Health and COVID-19: Early evidence of the pandemic’s impact: Scientific brief, 2 March 2022. 2022. Accessed: 27.05.2024. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1
Klinicheskie rekomendacii Ministerstva zdravooxraneniya Rossijskoj Federacii. Trevozhno-fobicheskie rasstrojstva u vzrosly’x. 2021. Accessed: 27.05.24. (In Russ.). https://cr.minzdrav.gov.ru/recomend/455_2
Stein DJ, Lim CCW, Roest A.M, et al. and WHO World Mental Health Survey Collaborators. The cross-national epidemiology of social anxiety disorder: Data from the World Mental Health Survey Initiative. BMC Med. 2017;15(1):143. https://doi.org/10.1186/s12916-017-0889-2
Kirpichenka AA, Baryshau AN. Anxiety and depression screening in general medical practice: the current state of the matter. Vestnik of Vitebsk State Medical University. 2020;19(5):8-16. (In Russ.). https://doi.org/10.22263/2312-4156.2020.5.8
Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.). https://doi.org/10.15829/1728-8800-2022-3235
Shishkova VN. Anxiety in subjects with cardiovascular disease: Current diagnostic strategies and therapeutic options. A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(8):710-715. (In Russ.). https://doi.org/10.26442/00403660.2023.08.202207
Smirnova MD, Svirida ON, Fofanova TV, et al. Subclinical depression and anxiety as an additional risk factor for cardiovascular events in low- and moderate-risk patients: data from 10-year follow-up. Cardiovascular Therapy and Prevention. 2021;20(4):2762. (In Russ.). https://doi.org/10.15829/1728-8800-2021-2762
Volpato E, Toniolo S, Pagnini F, Banfi P. The relationship between anxiety, depression and treatment adherence in chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstr Pulm Dis. 2021;16:2001-2021. https://doi.org/10.2147/copd.s313841
Willgoss TG, Yohannes AM. Anxiety disorders in patients with COPD: a systematic review. Resp Care. 2013;58(5):858-866. https://doi.org/10.4187/respcare.01862
Elbinoune I, Amine B, Shyen S, et al. Chronic neck pain and anxiety-depression: prevalence and associated risk factors. Pan African Med J. 2016;24:89. https://doi.org/10.11604/pamj.2016.24.89.8831
Bisby MA, Karin E, Scott AJ, et al. Examining the psychometric properties of brief screening measures of depression and anxiety in chronic pain: The Patient Health Questionnaire 2-item and Generalized Anxiety Disorder 2-item. Pain Pract. 2022;22(4):478-486. https://doi.org/10.1111/papr.13107
Lerman SF, Rudich Z, Brill S, et al. Longitudinal associations between depression, anxiety, pain, and pain-related disability in chronic pain patients. Psychosom Med. 2015;77(3):333-341. https://doi.org/10.1097/psy.0000000000000158
Shcherbakova IV, Krylatykh VYu, Bardenshteyn LM. The psycho-pharmacotherapy of anxiety disorders: problem actual view. Rossiiskii Meditsinskii Zhurnal. 2017;23(2):107-112 (In Russ.). https://doi.org/10.18821/0869-2106-2017-23-2-107-112
Kryzhanovskiy SM, Samushia MA, Iosava IK, Berestovoy MA. Adaptol effectiveness in the therapy of anxiety-depressive syndrome in patients with somatic pathologies: a systematic analysis. Kremlin Medicine. 2023;1:43-50. (In Russ.). https://doi.org/10.48612/cgma/ppb5-8g43-ut1g
Levin OS, Rachin SA. Effectiveness of Adaptol in the treatment of emotional disorders in patients with physical illnesses. Pharmacology & Pharmacotherapy. 2022;(5):68-72. (In Russ.). https://doi.org/10.46393/27132129_2022_5_68
Bunova AS, Shikova DV. Mobile applications for the control of anxiety and depression symptoms: search and quality evaluation. Russian Journal of Preventive Medicine. 2023;26(10):27-35. (In Russ.). https://doi.org/10.17116/profmed20232610127
Zamyatin KA, Nozdrachev DI, Solovieva MN. Mobile applications for anxiety and stress reduction: potential for preventing noncommunicable diseases. Russian Journal of Cardiology. 2021;26(9):4681. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4681
Morozova MA, Potanin SS, Beniashvili AG, et al. Validation of the Hospital Anxiety and Depression Scale Russian-language version in the general population. Russian Journal of Preventive Medicine. 2023;26(4):7-14. (In Russ.). https://doi.org/10.17116/profmed2023260417
Ababkov VA, Barisnikov K, Vorontzova-Wenger OV, et al. of the Russian version of the questionnaire «Scale of perceived stress-10». Vestnik of Saint-Petersburg University. Series 16. Psychology. Education. 2016;2:6-15. (In Russ.). https://doi.org/10.21638/11701/spbu16.2016.202
Akulova AI, Gaydukova IZ, Rebrov AP. Validation of the EQ-5D-5L version In Russia. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):351-355. (In Russ.). https://doi.org/10.14412/1995-4484-2018-351-355
Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. The Questionnaire Survey Method in Medicine on the Example of Treatment Adherence Scales. Rational Pharmacotherapy in Cardiology. 2020;17(4):576-583. (In Russ.). https://doi.org/10.20996/1819-6446-2021-08-02
Kotova OV, Belyaev AA, Akarachkova ES. State-of-the-art diagnostic and treatment modalities for anxiety and depression. Russian Medical Inquiry. 2021;5(10):648-653 (In Russ.). https://doi.org/10.32364/2587-6821-2021-5-10-648-653
Drissi N, Ouhbia S, Idrissib MAJ, Ghogho M. An analysis on self-management and treatment-related functionality and characteristics of highly rated anxiety apps. Int J Med Inf. 2020;141:104243. https://doi.org/10.1016/j.ijmedinf.2020.104243
Boettcher J, Magnusson K, Marklund A, et al. Adding a smartphone app to Internet-based self-help for social anxiety: a randomized controlled trial. Comput Hum Behav. 2018;87: 34-39. https://doi.org/10.1016/j.chb.2018.04.052
Domhardt M, Geßlein H, Rezori RE, Baumeister H. Internet- and mobile-based interventions for anxiety disorders: a meta-analytic review of intervention components. Depression Anxiety. 2019;36(3):213-224. https://doi.org/10.1002/da.22860
Graham AK, Greene CJ, Kwasny MJ, et al. Coached mobile app platform for the treatment of depression and anxiety among primary care patients: a randomized clinical trial. JAMA Psychiatry. 2020;77(9):906-914. https://doi.org/10.1001/jamapsychiatry.2020.1011
Proudfoot J, Clarke J, Birch MR, et al. Impact of a mobile phone and web program on symptom and functional outcomes for people with mild-to-moderate depression, anxiety and stress: a randomised controlled trial. BMC Psychiatry. 2013;13:312. https://doi.org/10.1186/1471-244x-13-312
Rozanov VA, Samerkhanova KM. Mobile applications for mental health self-management: a review of customers’ opinions. Russian Journal of Telemedicine and E-Health. 2022;8(2)7-20. (In Russ.). https://doi.org/10.29188/2712-9217-2022-8-2-7-20
Linardon J, Cuijpers P, Carlbring P, et al. The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of randomized controlled trials. World Psychiatry. 2019;18(3):325-336. https://doi.org/10.1002/wps.20673

Close metadata